Cannabinoid Encyclopedia

How cannabinoids work

What is COX-2?

A simple explanation of COX-2, why cannabinoid researchers study it, and what its biology can and cannot tell us.

Updated July 2026 27 research sources Human and early research

The short answer

Where COX-2 fits into cannabinoid biology

COX-2 is a biological target studied to understand how cannabinoids affect cells and signaling. Research on THC, CBG, CBC, and THCV helps explain possible mechanisms. This page brings together 6 human-study sources, 12 research reviews, and 9 lab, animal, or mechanism sources. The source set includes human research as well as earlier-stage studies. A mechanism alone does not prove that a cannabinoid will produce a health benefit in people. 1

Choose your next step

Want the quick path or the full picture?

Use this guide the way you need to. Start with the practical question, then open the study detail only when it helps answer something about COX-2.

What researchers studiedSee the main areas and the evidence behind each one. Safety and limitsKeep product, dose, medications, and context in view. Open the sourcesGo directly to the studies and references used here.

Key takeaways

What to know first

  1. 1

    Research on COX-2 covers THC, CBG, and CBC; those areas should not be combined into one claim. 1

  2. 2

    The source set includes human research as well as earlier-stage studies. 2

  3. 3

    Dose, formulation, route, study population, and outcome can change how closely a study applies to a real-world question. 3

Research areas

What researchers studied about COX-2

These are the main questions represented in the current literature. Each link opens a source used to build the overview.

Human research included

THC

Studies examine how THC connects with COX-2 or closely related target biology. These findings help explain signaling and pharmacology, not a guaranteed health effect. 2

Preclinical and mechanism-focused

CBG

Studies examine how CBG connects with COX-2 or closely related target biology. These findings help explain signaling and pharmacology, not a guaranteed health effect. 3

Too limited for a firm answer

CBC

Studies examine how CBC connects with COX-2 or closely related target biology. These findings help explain signaling and pharmacology, not a guaranteed health effect. 4

Mostly mechanism-focused

THCV

Studies examine how THCV connects with COX-2 or closely related target biology. These findings help explain signaling and pharmacology, not a guaranteed health effect. 5

Too limited for a firm answer

CBDA

Studies examine how CBDA connects with COX-2 or closely related target biology. These findings help explain signaling and pharmacology, not a guaranteed health effect. 6

Human and early-stage research

Endocannabinoids

Studies examine how Endocannabinoids connects with COX-2 or closely related target biology. These findings help explain signaling and pharmacology, not a guaranteed health effect. 7

How strong is the research?

Not every study answers the same question

This page separates research in people, research reviews, and earlier-stage biology before interpreting the larger question.

6 sources

Human studies

Research involving people is closest to everyday health questions. The product, dose, population, and outcome still determine what each study can show.

12 sources

Reviews and evidence summaries

Reviews can compare several studies at once. Their conclusion is only as strong and as relevant as the studies they include.

9 sources

Lab, animal, and mechanism research

Early-stage research can explain biological interest. It cannot, by itself, show that the same effect happens in people.

What these studies actually looked at

The research on COX-2 is not one kind of study. This source set includes 12 narrative or expert reviews, 11 animal studies, 1 cell or laboratory study, and 1 clinical study in people. 3

The recorded populations or models include animal models (8 sources), people or patients (7 sources), and cells or tissue models (4 sources). A result from one group or model should not be assumed to apply to another. 4

The most common recorded outcome focus is endocannabinoid enzyme activity or metabolic mechanisms (16 sources), inflammation-related or immune outcomes (5 sources), and nausea-related or inflammation-related outcomes (2 sources). Closely related outcome names can still describe different measurements. 5

The COX-2 source set also contains findings or reviews that remain too limited, indirect, or mixed for a broad answer. That uncertainty is part of the result, not an empty space to fill with assumptions. 6

Examples from the literature

What did the studies actually look at?

Each example names the research question and the study details recorded for that source.

narrative or expert review

Potential of Fatty Acid Amide Hydrolase (FAAH), Monoacylglycerol Lipase (MAGL), and Diacylglycerol Lipase (DAGL) Enzymes as Targets for Obesity Treatment: A Narrative Review.

On this page, this source examines Endocannabinoids activity involving endocannabinoid enzyme activity or metabolic mechanisms. 1

Study type
narrative or expert review
Population or model
people or patients
Outcome focus
endocannabinoid enzyme activity or metabolic mechanisms
Evidence stage
evidence still limited

narrative or expert review

FAAH and MAGL inhibitors: therapeutic opportunities from regulating endocannabinoid levels.

On this page, this source examines THC activity involving endocannabinoid enzyme activity or metabolic mechanisms. 2

Study type
narrative or expert review
Population or model
cells or tissue models
Outcome focus
endocannabinoid enzyme activity or metabolic mechanisms
Evidence stage
evidence still limited

animal study

Beneficial effect of the non-psychotropic plant cannabinoid cannabigerol on experimental inflammatory bowel disease.

On this page, this source examines CBG and inflammation-related outcomes. 3

Study type
animal study
Population or model
people or patients
Outcome focus
inflammation-related or immune outcomes
Evidence stage
mechanism-focused research

narrative or expert review

Therapeutic potential of acidic cannabinoids: an update.

On this page, this source examines CBG and pain-related outcomes, CBC and inflammation-related outcomes, and CBDA and nausea-related or inflammation-related outcomes. 4

Study type
narrative or expert review
Population or model
pediatric, adolescent, or developmental context
Outcome focus
pain-related outcomes and inflammation-related or pain-related outcomes and other recorded details
Evidence stage
evidence still limited

animal study

Pure Δ9-tetrahydrocannabivarin and a Cannabis sativa extract with high content in Δ9-tetrahydrocannabivarin inhibit nitrite production in murine peritoneal macrophages.

On this page, this source examines THCV activity involving TRP channel activity or ionotropic cannabinoid target mechanisms, THCV activity involving receptor, target, metabolic, or pharmacology mechanisms, and THCV and inflammation-related outcomes and other related questions. 5

Study type
animal study
Population or model
animal models
Outcome focus
tRP channel activity or ionotropic cannabinoid target mechanisms and receptor, target, metabolic, or pharmacology mechanisms and other recorded details
Evidence stage
mechanism-focused research

Safety and limits

What should readers keep in mind?

Research on COX-2 should be read beside safety. A compound can be non-intoxicating or naturally occurring and still have pharmacologic effects, side effects, interactions, or product-quality concerns. 9

Research doses are descriptions of what a study tested. They are not personal dosing instructions. Questions involving medications, pregnancy, children, driving, liver health, heart health, or serious symptoms deserve professional medical guidance.

Drug interactions Pregnancy and children Driving and impairment All safety topics

Common questions

Questions people ask

What does COX-2 do?

COX-2 is studied as part of cannabinoid-related biology and signaling. The exact role depends on the tissue, compound, and experimental setting. 7

Does a biological mechanism prove a health effect?

No. A mechanism can explain why an idea is plausible, but human studies are needed to test whether it changes a health outcome. 8

What research is linked to COX-2?

The main areas on this page include THC, CBG, CBC, and THCV. The source links show the study type behind each area. 9

Sources

Read the research

The numbered sources below support the main overview. Links open the PubMed record or DOI in a new tab.

  1. 1
    Potential of Fatty Acid Amide Hydrolase (FAAH), Monoacylglycerol Lipase (MAGL), and Diacylglycerol Lipase (DAGL) Enzymes as Targets for Obesity Treatment: A Narrative Review. narrative or expert review; evidence still limited PubMed 34959715 DOI 10.3390/ph14121316
  2. 2
    FAAH and MAGL inhibitors: therapeutic opportunities from regulating endocannabinoid levels. narrative or expert review; evidence still limited PubMed 20047159
  3. 3
    Beneficial effect of the non-psychotropic plant cannabinoid cannabigerol on experimental inflammatory bowel disease. animal study; mechanism-focused research PubMed 23415610 DOI 10.1016/j.bcp.2013.01.017
  4. 4
    Therapeutic potential of acidic cannabinoids: an update. narrative or expert review; evidence still limited PubMed 41545891 DOI 10.1186/s42238-026-00387-y
  5. 5
    Pure Δ9-tetrahydrocannabivarin and a Cannabis sativa extract with high content in Δ9-tetrahydrocannabivarin inhibit nitrite production in murine peritoneal macrophages. animal study; mechanism-focused research PubMed 27498155 DOI 10.1016/j.phrs.2016.07.045
  6. 6
    Cannabis sativa L. and Nonpsychoactive Cannabinoids: Their Chemistry and Role against Oxidative Stress, Inflammation, and Cancer. narrative or expert review; evidence still limited PubMed 30627539 DOI 10.1155/2018/1691428
  7. 7
    Potential application of endocannabinoid system agents in neuropsychiatric and neurodegenerative diseases-focusing on FAAH/MAGL inhibitors. narrative or expert review; evidence still limited PubMed 32203086 DOI 10.1038/s41401-020-0385-7
  8. 8
    Targeting the endocannabinoid system for management of HIV-associated neuropathic pain: A systematic review. clinical study in people; preclinical research PubMed 34179865 DOI 10.1016/j.ibneur.2021.01.004
  9. 9
    Palmitoylethanolamide is a new possible pharmacological treatment for the inflammation associated with trauma. narrative or expert review; evidence still limited PubMed 22697514
  10. 10
    Biochemical and pharmacological characterization of human α/β-hydrolase domain containing 6 (ABHD6) and 12 (ABHD12). human research PubMed 22969151 DOI 10.1194/jlr.m030411
  11. 11
    Impact of tetrahydrocannabinol on the endocannabinoid 2-arachidonoylglycerol metabolism: ABHD6 and ABHD12 as novel players in human placenta. human research PubMed 32829065 DOI 10.1016/j.bbalip.2020.158807
  12. 12
    Chemical Probes for Investigating the Endocannabinoid System. narrative or expert review; evidence still limited PubMed 39747798 DOI 10.1007/7854_2024_563
See all 27 research sources

This complete source list is the deeper research layer for the page. Study type and evidence context are shown when they are available in the current record.

  1. Cannabis sativa L. and Nonpsychoactive Cannabinoids: Their Chemistry and Role against Oxidative Stress, Inflammation, and Cancer. narrative or expert review; evidence still limited / 1 linked research note PubMed 30627539
  2. Therapeutic potential of acidic cannabinoids: an update. narrative or expert review; evidence still limited / 3 linked research notes PubMed 41545891
  3. Targeting the endocannabinoid system for management of HIV-associated neuropathic pain: A systematic review. clinical study in people; preclinical research / 1 linked research note PubMed 34179865
  4. Pure Δ9-tetrahydrocannabivarin and a Cannabis sativa extract with high content in Δ9-tetrahydrocannabivarin inhibit nitrite production in murine peritoneal macrophages. animal study; mechanism-focused research / 4 linked research notes PubMed 27498155
  5. Maternal immune activation impairs endocannabinoid signaling in the mesolimbic system of adolescent male offspring. animal study; preclinical research / 1 linked research note PubMed 36746342
  6. Potential application of endocannabinoid system agents in neuropsychiatric and neurodegenerative diseases-focusing on FAAH/MAGL inhibitors. narrative or expert review; evidence still limited / 1 linked research note PubMed 32203086
  7. Inhibition of endocannabinoid hydrolases MAGL, FAAH and ABHD6 by AKU-005 reduces ex vivo cortical spreading depression. animal study; mechanism-focused research / 1 linked research note PubMed 40269679
  8. The role of endocannabinoid pathway in the neuropathology of Alzheimer's disease: Can the inhibitors of MAGL and FAAH prove to be potential therapeutic targets against the cognitive impairment associated with Alzheimer's disease? narrative or expert review; evidence still limited / 1 linked research note PubMed 34217798
  9. FAAH and MAGL inhibitors: therapeutic opportunities from regulating endocannabinoid levels. narrative or expert review; evidence still limited / 1 linked research note PubMed 20047159
  10. Potential of Fatty Acid Amide Hydrolase (FAAH), Monoacylglycerol Lipase (MAGL), and Diacylglycerol Lipase (DAGL) Enzymes as Targets for Obesity Treatment: A Narrative Review. narrative or expert review; evidence still limited / 1 linked research note PubMed 34959715
  11. Inhibition of endocannabinoid synthesis enzymes DAGL and NAPE-PLD transiently lowers body weight and alters glucose homeostasis during a high-fat diet challenge in mice. animal study; mechanism-focused research / 1 linked research note PubMed 41092478
  12. Subcellular localization of NAPE-PLD and DAGL-α in the ventromedial nucleus of the hypothalamus by a preembedding immunogold method. animal study; preclinical research / 1 linked research note PubMed 24346263
  13. Microglial morphological/inflammatory phenotypes and endocannabinoid signaling in a preclinical model of periodontitis and depression. animal study; mechanism-focused research / 1 linked research note PubMed 39245706
  14. Critical enzymes involved in endocannabinoid metabolism. narrative or expert review; evidence still limited / 1 linked research note PubMed 17346227
  15. Chemical Probes for Investigating the Endocannabinoid System. narrative or expert review; evidence still limited / 1 linked research note PubMed 39747798
  16. Structural properties and role of the endocannabinoid lipases ABHD6 and ABHD12 in lipid signalling and disease. narrative or expert review; evidence still limited / 1 linked research note PubMed 30564946
  17. Impact of tetrahydrocannabinol on the endocannabinoid 2-arachidonoylglycerol metabolism: ABHD6 and ABHD12 as novel players in human placenta. human research / 1 linked research note PubMed 32829065
  18. The serine hydrolases MAGL, ABHD6 and ABHD12 as guardians of 2-arachidonoylglycerol signalling through cannabinoid receptors. narrative or expert review; evidence still limited / 1 linked research note PubMed 21418147
  19. Deregulation of the endocannabinoid system and therapeutic potential of ABHD6 blockade in the cuprizone model of demyelination. animal study; preclinical research / 1 linked research note PubMed 30075103
  20. Biochemical and pharmacological characterization of human α/β-hydrolase domain containing 6 (ABHD6) and 12 (ABHD12). human research / 1 linked research note PubMed 22969151
  21. Beneficial effect of the non-psychotropic plant cannabinoid cannabigerol on experimental inflammatory bowel disease. animal study; mechanism-focused research / 1 linked research note PubMed 23415610
  22. Cannabigerol Exerts In Vivo and In Vitro Anti-Inflammatory Effects via Inhibition of the MAPK and NF-κB Pathways. animal study; mechanism-focused research / 1 linked research note PubMed 41423277
  23. Cannabigerol as an anti-inflammatory agent altering the level of arachidonic acid derivatives in the colon tissue of rats subjected to a high-fat high-sucrose diet. animal study; preclinical research / 1 linked research note PubMed 39128189
  24. Pharmacological Aspects and Biological Effects of Cannabigerol and Its Synthetic Derivatives. narrative or expert review; evidence still limited / 2 linked research notes PubMed 36397993
  25. The cannabinoid TRPA1 agonist cannabichromene inhibits nitric oxide production in macrophages and ameliorates murine colitis. animal study; mechanism-focused research / 1 linked research note PubMed 23373571
  26. Phytocannabinoids Act Synergistically with Non-Steroidal Anti-Inflammatory Drugs Reducing Inflammation in 2D and 3D In Vitro Models. cell or laboratory study; mechanism-focused research / 1 linked research note PubMed 36559009
  27. Palmitoylethanolamide is a new possible pharmacological treatment for the inflammation associated with trauma. narrative or expert review; evidence still limited / 1 linked research note PubMed 22697514